Drug Profile
Research programme: plasmid DNA therapeutics - Alma Bio Therapeutics
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Alma Bio Therapeutics
- Class DNA
- Mechanism of Action Heat-shock protein modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Rheumatic disorders
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Crohn's-disease in France
- 28 Jul 2021 No recent reports of development identified for research development in Rheumatic-disorders in France
- 26 Jun 2017 Early research in Rheumatic disorders in France (unspecified route)